Skip to content

Study · Animal study (in vivo) · 2021

2 results

SS31 Ameliorates Podocyte Injury via Inhibiting OMA1-Mediated Hydrolysis of OPA1 in Diabetic Kidney Disease.

Yang Q, Xie W, Wang X, Luo J, Zhou Y, Cao H, Sun Q, Jiang L, Yang J

Frontiers in pharmacology31 Jan 2022Cited by 33 (Europe PMC)

PMID36338294 (opens in a new tab)PMCIDPMC9629008 (opens in a new tab)DOI10.3389/fphar.2021.707006 (opens in a new tab)PepBankPUB-36338294
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Diabetic kidney disease (DKD) is currently one of the leading causes of end-stage renal disease (ESRD). Mitochondrial dysfunction in podocyte is involve in DKD development. However, whether early mitochondrial stabilization delays or reverses DKD progression has not been elucidated. SS31 is a novel tetrapeptide compound that targets the inner mitochondrial membrane and protects mitochondria by reducing ROS and inhibiting cardiolipin oxidation. Our study discovered that SS31 might have a long-term podocyte protection in DKD. In this study, we examined the glomerular pathological damage and proteinuria at different stages of diabetes. Results revealed that podocyte mitochondrial injury appeared at the early stage of DKD. Early treatment with SS31 could protect podocyte and alleviate the development of DKD via inhibiting OMA1-mediated hydrolysis of OPA1. Those data indicate that SS31 might be a promising agent in delaying the development of DKD and OMA1-mediated hydrolysis of OPA1 in mitochondria, and SS31 is a novel therapeutic target for the treatment of DKD.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic kidney disease, early treatment with SS31 protected podocytes and alleviated the development of DKD.

    In plain wordsIn a diabetic kidney disease model, early SS31 treatment protected kidney filter cells and slowed disease development.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePodocyte protection and development of DKD with early treatment
    Study

    n: not reported in source

    Diabetic kidney disease
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Early treatment with SS31 could protect podocyte and alleviate the development of DKD via inhibiting OMA1-mediated hydrolysis of OPA1.
    1 context sentence
    Summary · context
    In this study, we examined the glomerular pathological damage and proteinuria at different stages of diabetes.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In diabetic kidney disease, SS31 inhibited OMA1-mediated hydrolysis of OPA1.

    In plain wordsIn a diabetic kidney disease model, SS31 blocked the OMA1 enzyme from breaking down OPA1 in mitochondria.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseOMA1-mediated hydrolysis of OPA1
    Study

    n: not reported in source

    Diabetic kidney disease
    Outcome group
    Mitochondrial function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Early treatment with SS31 could protect podocyte and alleviate the development of DKD via inhibiting OMA1-mediated hydrolysis of OPA1.
    1 context sentence
    Summary · context
    In this study, we examined the glomerular pathological damage and proteinuria at different stages of diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.